by Elec23 | Mar 11, 2026 | News&events, VisMederi
VisMederi highlighted its collaboration with Sumitomo Pharma Co., Ltd. and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in the European Phase 1 clinical programme evaluating a universal influenza vaccine candidate formulated with...
by Elec23 | Mar 3, 2026 | News&events, VisMederi
VisMederi is a partner in NOFLU, a European consortium selected by the European Union to support the early clinical development of a next-generation pandemic influenza vaccine. The project is coordinated by NIVI Development, the development arm of the Novo Nordisk...
